Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 3:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 1,546 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Ulcers Clear all
Completed Phase 3 Interventional Results available

A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

NCT03524092
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Mirikizumab SC, Mirikizumab IV, Placebo SC
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
57
States / cities
Dothan, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 23, 2026, 3:29 PM EDT
Recruiting Phase 4 Interventional

A Non-Randomized Open Label Clinical Trial Evaluating DermaBind TL

NCT07172893
View directory record Official record
Conditions
Diabetic Foot Ulcer (DFU), Venous Leg Ulcer (VLU)
Interventions
DermaBind TL
Biological
Lead sponsor
HealthTech Wound Care
Industry
Eligibility
18 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
10
States / cities
DeLand, Florida • Palm Beach Gardens, Florida • Sweetwater, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 23, 2026, 3:29 PM EDT
Recruiting Not applicable Interventional

Marginal Ulcer Healing With Low-Thermal Argon Plasma Endoscopic Treatment

NCT06543316
View directory record Official record
Conditions
Roux-en-y Anastomosis Site, Marginal Ulcer, Marginal Ulcer (Peptic) or Erosion, Ulcer, Ulcer, Gastric, Ulcer Gastrointestinal, Abdominal Pain, Nausea, Vomiting, GastroIntestinal Bleeding, Dysphagia, Ulcer Gastrojejunal
Interventions
Low Thermal Plasma (LTP) Treatment, Standard of Care Ulcer Treatment (typically PPI Administration)
Procedure · Other
Lead sponsor
Christopher C. Thompson, MD, MSc
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 23, 2026, 3:29 PM EDT
Terminated Not applicable Interventional Results available

VenaSeal Spectrum: Global Post-Market Randomized Controlled Trial

NCT03820947
View directory record Official record
Conditions
Venous Reflux
Interventions
VenaSeal™ System, Endothermal Ablation (ETA), Surgical Stripping
Device · Procedure
Lead sponsor
Medtronic Endovascular
Industry
Eligibility
18 Years and older
Enrollment
506 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
12
States / cities
Prescott Valley, Arizona • Tucson, Arizona • Fresno, California + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 23, 2026, 3:29 PM EDT
Completed Not applicable Interventional Results available

An RCT on Preventing Pressure Ulcers With Wheelchair Seat Cushions

NCT00178126
View directory record Official record
Conditions
Pressure Ulcer
Interventions
Skin Protection Wheelchair Seat Cushion, Segmented Foam Wheelchair Seat Cushion
Device
Lead sponsor
University of Pittsburgh
Other
Eligibility
65 Years and older
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 2, 2017 · Synced Oct 23, 2026, 3:29 PM EDT
Recruiting Phase 2 Interventional

Aquamin® for Prevention of Ulcerative Colitis J-Pouch-associate Intestinal Inflammation

NCT07501078
View directory record Official record
Conditions
Ulcerative Colitis, Ileal Pouch
Interventions
Aquamin, Placebo
Drug
Lead sponsor
Muhammad N Aslam, MD
Other
Eligibility
18 Years to 80 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 23, 2026, 3:29 PM EDT
Terminated No phase listed Observational

3C Patch® Medicare Claims Study

NCT03997526
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
3C Patch
Device
Lead sponsor
Reapplix
Other
Eligibility
Not listed
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
6
States / cities
Phoenix, Arizona • Natchitoches, Louisiana • Opelousas, Louisiana + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Oct 23, 2026, 3:29 PM EDT
Completed Not applicable Interventional

Human Amniotic Membrane Grafting and Standard of Care Versus Standard of Care Alone in the Treatment of Venous Leg Ulcers

NCT01552447
View directory record Official record
Conditions
Venous Leg Ulcer
Interventions
EpiFix, Compression Therapy
Other
Lead sponsor
MiMedx Group, Inc.
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
5
States / cities
Boca Raton, Florida • Framingham, Massachusetts • Tulsa, Oklahoma + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2016 · Synced Oct 23, 2026, 3:29 PM EDT
Completed Not applicable Interventional

DHACM vs Other Commercially Available Treatments

NCT01921491
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
Dressing Application, Offloading
Procedure · Device
Lead sponsor
MiMedx Group, Inc.
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Tulsa, Oklahoma • Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 4, 2020 · Synced Oct 23, 2026, 3:29 PM EDT
Completed Phase 4 Interventional

Asacol Dosing Study for Active Ulcerative Colitis

NCT00194818
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Asacol (mesalamine)
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 15, 2008 · Synced Oct 23, 2026, 3:29 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study to Evaluate the Safety and Efficacy of Hydrocortisone Acetate Suppositories

NCT04469686
View directory record Official record
Conditions
Ulcerative Proctitis
Interventions
Twice daily 90 mg hydrocortisone acetate suppository administered with Sephure applicator, Once daily 90 mg hydrocortisone acetate or placebo suppository administered with Sephure applicator, Twice daily placebo suppository administered with Sephure applicator
Combination Product
Lead sponsor
Cristcot HCA LLC
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
51
States / cities
Huntsville, Alabama • Apple Valley, California • Camarillo, California + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 23, 2026, 3:29 PM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)

NCT07463183
View directory record Official record
Conditions
Colitis Ulcerative, Ulcerative Colitis
Interventions
MK-8690, Placebo
Drug · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
11
States / cities
Anaheim, California • Coronado, California • Colorado Springs, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 23, 2026, 3:29 PM EDT
Completed Phase 2 Interventional Results available

Examining the Efficacy of Fecal Microbiota Transplantation (FMT) and Dietary Fiber in Patients With Ulcerative Colitis

NCT03998488
View directory record Official record
Conditions
Ulcerative Colitis, Inflammatory Bowel Diseases
Interventions
Fecal Microbiota Transplantation, Psyllium Husk Powder
Drug · Dietary Supplement
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 89 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 3, 2025 · Synced Oct 23, 2026, 3:29 PM EDT
Completed Not applicable Interventional Results available

In-Home Assessment of a Smart Foot Mat for Prevention of Diabetic Foot Ulcers

NCT02647346
View directory record Official record
Conditions
Foot Ulcer, Diabetic
Interventions
Daily use of podimetrics smart-foot mat
Device
Lead sponsor
Podimetrics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
8
States / cities
Phoenix, Arizona • Tucson, Arizona • Castro Valley, California + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2020 · Synced Oct 23, 2026, 3:29 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Clinical Trial Evaluating Gastrointestinal Damage Following Administration PL3100 or Naproxen in At-Risk Adults

NCT01139190
View directory record Official record
Conditions
Gastroduodenal Ulcerations, Erosion
Interventions
PL3100, Naproxen
Drug
Lead sponsor
PLx Pharma
Industry
Eligibility
50 Years to 75 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
2
States / cities
Dallas, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 11, 2016 · Synced Oct 23, 2026, 3:29 PM EDT
Terminated Phase 3 Interventional

Study of Remodulin in Patients With Critical Limb Ischemia With No Planned Revascularization Procedures

NCT00060996
View directory record Official record
Conditions
Critical Limb Ischemia, Peripheral Vascular Disease, Foot Ulcers, Rest Leg Pain
Interventions
Remodulin® (treprostinil sodium) Injection
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
7
States / cities
Tampa, Florida • Worcester, Massachusetts • Minneapolis, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2013 · Synced Oct 23, 2026, 3:29 PM EDT
Completed Phase 4 Interventional

A Study to Assess the Concentrations of Risankizumab in the Breast Milk of Adult Lactating Women With Inflammatory Bowel Disease

NCT06346288
View directory record Official record
Conditions
Inflammatory Bowel Disease
Interventions
Breast Milk Sampling, Risankizumab
Procedure · Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 23, 2026, 3:29 PM EDT
Completed Phase 2 Interventional Results available

A Study of Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

NCT03662542
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Guselkumab Dose 1, Guselkumab Dose 2, Golimumab Dose 1, Golimumab Dose 2, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
14
States / cities
San Diego, California • Colorado Springs, Colorado • Tampa, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Oct 23, 2026, 3:29 PM EDT
Recruiting Phase 3 Interventional

A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)

NCT06568627
View directory record Official record
Conditions
Venous Leg Ulcer (VLU)
Interventions
EscharEx (EX-03), Placebo (Gel vehicle)
Drug
Lead sponsor
MediWound Ltd
Industry
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
19
States / cities
Phoenix, Arizona • Fresno, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 23, 2026, 3:29 PM EDT
Completed Phase 1 Interventional

Safety, Tolerability, and Pharmacokinetics of Oral NX-13 in Active Ulcerative Colitis

NCT04862741
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
NX-13 250mg IR, NX-13 500mg IR, NX-13 500mg MR, Placebo
Drug
Lead sponsor
Landos Biopharma Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
22
States / cities
Huntsville, Alabama • Lancaster, California • Mission Viejo, California + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Oct 23, 2026, 3:29 PM EDT
Completed Phase 2 Interventional

Study Evaluating Pantoprazole in Peptic Ulcer Hemorrhage

NCT00037570
View directory record Official record
Conditions
Peptic Ulcer Hemorrhage
Interventions
Pantoprazole
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
6
States / cities
Los Angeles, California • San Diego, California • Cincinnati, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2013 · Synced Oct 23, 2026, 3:29 PM EDT
Completed Not applicable Interventional

Broccoli Sprouts for Mild Ulcerative Colitis

NCT05507931
View directory record Official record
Conditions
Ulcerative Colitis, Ulcerative Colitis Chronic Mild
Interventions
1 Serving of broccoli sprouts, 3 Servings of broccoli sprouts
Dietary Supplement
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 23, 2026, 3:29 PM EDT
Recruiting Phase 4 Interventional

Feasibility Pilot Sequential Multiple Assignment Randomized Trial (SMART) for Acute Severe Ulcerative Colitis

NCT05867329
View directory record Official record
Conditions
Ulcerative Colitis Acute
Interventions
Cyclosporine Injection (IV), Cyclosporine Oral Product, Upadacitinib Extended Release Oral Tablet, Intravenous Methylprednisolone, Prednisone Oral Product
Drug
Lead sponsor
Berinstein, Jeffrey
Other
Eligibility
18 Years to 75 Years
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 23, 2026, 3:29 PM EDT
Suspended No phase listed Observational Accepts healthy volunteers

Non-Invasive Testing to Evaluate Wound Healing in Diabetes

NCT04232631
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
SnapshotNIR, Kent Imaging
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 89 Years
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 23, 2026, 3:29 PM EDT